These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 30498775)

  • 1. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis.
    Tvorogov D; Thomas D; Liau NPD; Dottore M; Barry EF; Lathi M; Kan WL; Hercus TR; Stomski F; Hughes TP; Tergaonkar V; Parker MW; Ross DM; Majeti R; Babon JJ; Lopez AF
    Sci Adv; 2018 Nov; 4(11):eaat3834. PubMed ID: 30498775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications.
    Ross DM; Babon JJ; Tvorogov D; Thomas D
    Haematologica; 2021 May; 106(5):1244-1253. PubMed ID: 33472356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nuclear-Cytoplasmic Transport Is a Therapeutic Target in Myelofibrosis.
    Yan D; Pomicter AD; Tantravahi S; Mason CC; Senina AV; Ahmann JM; Wang Q; Than H; Patel AB; Heaton WL; Eiring AM; Clair PM; Gantz KC; Redwine HM; Swierczek SI; Halverson BJ; Baloglu E; Shacham S; Khorashad JS; Kelley TW; Salama ME; Miles RR; Boucher KM; Prchal JT; O'Hare T; Deininger MW
    Clin Cancer Res; 2019 Apr; 25(7):2323-2335. PubMed ID: 30563936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cells.
    Machado-Neto JA; de Melo Campos P; Favaro P; Lazarini M; da Silva Santos Duarte A; Lorand-Metze I; Costa FF; Saad ST; Traina F
    Oncotarget; 2015 Oct; 6(30):29573-84. PubMed ID: 26356819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
    Ueda F; Tago K; Tamura H; Funakoshi-Tago M
    J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. How many JAK inhibitors in myelofibrosis?
    Ferreira BV; Harrison C
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):187-95. PubMed ID: 25189729
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intrinsic resistance to JAK2 inhibition in myelofibrosis.
    Kalota A; Jeschke GR; Carroll M; Hexner EO
    Clin Cancer Res; 2013 Apr; 19(7):1729-39. PubMed ID: 23386690
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis.
    Verstovsek S; Kantarjian H; Mesa RA; Pardanani AD; Cortes-Franco J; Thomas DA; Estrov Z; Fridman JS; Bradley EC; Erickson-Viitanen S; Vaddi K; Levy R; Tefferi A
    N Engl J Med; 2010 Sep; 363(12):1117-27. PubMed ID: 20843246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
    Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
    Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ruxolitinib.
    Becker H; Engelhardt M; von Bubnoff N; Wäsch R
    Recent Results Cancer Res; 2014; 201():249-57. PubMed ID: 24756798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of JAK2/STAT3/SOCS3 signaling attenuates atherosclerosis in rabbit.
    Yang X; Jia J; Yu Z; Duanmu Z; He H; Chen S; Qu C
    BMC Cardiovasc Disord; 2020 Mar; 20(1):133. PubMed ID: 32169038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.
    Deininger M; Radich J; Burn TC; Huber R; Paranagama D; Verstovsek S
    Blood; 2015 Sep; 126(13):1551-4. PubMed ID: 26228487
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of myelofibrosis: JAK inhibition and beyond.
    Stahl M; Zeidan AM
    Expert Rev Hematol; 2017 May; 10(5):459-477. PubMed ID: 28395559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Janus kinase (JAK) inhibitors in the treatment of neoplastic and inflammatory disorders.
    Roskoski R
    Pharmacol Res; 2022 Sep; 183():106362. PubMed ID: 35878738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
    Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
    Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proliferation and survival signaling from both Jak2-V617F and Lyn involving GSK3 and mTOR/p70S6K/4EBP1 in PVTL-1 cell line newly established from acute myeloid leukemia transformed from polycythemia vera.
    Nagao T; Kurosu T; Umezawa Y; Nogami A; Oshikawa G; Tohda S; Yamamoto M; Miura O
    PLoS One; 2014; 9(1):e84746. PubMed ID: 24404189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
    Hobbs GS; Rozelle S; Mullally A
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent foot ulcer due to ruxolitinib therapy for primary myelofibrosis.
    Del Rosario M; Tsai H; Dasanu CA
    J Oncol Pharm Pract; 2018 Apr; 24(3):226-228. PubMed ID: 28436280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Should we be treating lower risk myelofibrosis patients with a JAK2 inhibitor?
    Lancman G; Mascarenhas J
    Expert Rev Hematol; 2017 Jan; 10(1):23-28. PubMed ID: 27882812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.